If you are having problems viewing this page, load here

GXPNews.com - FDA News and Announcements - March 01 - March 05, 2010

The once a week newsletter reporting on what's new with the Food and Drug Administration (FDA)
Distributed by the leader in Federal Regulations,
GMP Publications & FDA.COM - Feedback:
GXPNews Editor

GMP Publications Mini-Regulation handbooks - April 1 2010 FDA.COM Food and Drug Assistance for Industry and Consumers

Drug GMP Handbooks  |  Clinical Handbooks  |  Device Handbooks  |  Biological Handbooks
GLP Master Handbook -
Clinical Master Guide - Canadian GMPs - Pharmacovigilance Vol. 9a Electronic Systems

GMP Publications FDA Mini-Regulation Handbooks
Books>Pharma GMPsMedical DeviceClinicalFood-Diet-CosmeticBiologic-Cell-BloodLaboratoryPart 11EU-Can-Misc.
Business B2B for the Regulated Industry Sparta Systems Track Wise Interphex 2010

Stay up to date with the FDA CFR changes - Enter Email:     Archive

 Save 10% on all Code of Federal Regulations (CFRs) Pre-Orders till April 1, 2010       Use Coupon Number 100401-10

FDA Press Announcements | Stay current with the FDA Rule Updates | Pick up your free CFRs at Interphex!

Center for Drug Evaluation &
Research (CDER) News
Drug Approvals - Meetings - Links

Center for Biologics Evaluation
& Research (CBER)
Meetings - Links

Center for Device &
Radiological Health (CDRH)
Meetings - Links

Federal Register - Meetings, Notices, &  Rule Changes

CDER NEWS
Drug Approvals
March 5, 2010
  • Adalat (nifedipine) Extended-Release Tablets, Bayer HealthCare, Labeling Revision
  • Avelox (moxifloxacin hydrochloride) Tablets, Bayer HealthCare Pharmaceuticals, Inc., Labeling Revision
  • Avelox in Sodium Chloride 0.8% in Plastic Container (moxifloxacin hydrochloride) I.V. Injection, Bayer HealthCare Pharmaceuticals, Inc., Labeling Revision
  • ChloraPrep One-Step Sepp (chlorhexidine gluconate and isopropyl alcohol) Topical Swab, CareFusion, LLC, Labeling Revision
  • Femara (letrozole) Tablets, Novartis Pharmaceuticals Corporation, Efficacy Supplement with Clinical Data to Support
  • Fluvastatin Capsules, Teva Pharmaceuticals, Tentative Approval
  • Invega (paliperidone) Extended-Release Tablets, Johnson & Johnson Pharmaceutical, Labeling Revision
  • Levetiracetam Oral Solution, Wockhardt, Approval
  • Rapaflo (silodosin) Capsules, Watson Laboratories, Inc., Labeling Revision
  • Xifaxan (rifaximin) Tablets, Salix Pharmaceuticals, Inc., Labeling Revision
  • Zocor (simvastatin) Tablets, Merck & Co., Inc., Labeling Revision 

March 3, 2010

  • Exalgo (hydromorphone hrdrochloride) Extended-Release Tablets, ALZA Corporation, Approval
  • Fosamax (alendronate sodium) Tablets, Merck & Co., Inc., Labeling Revision
  • Fosamax (alendronate sodium) Oral Solution, Merck & Co., Inc., Labeling Revision
  • Fosamax Plus D (alendronate sodium and cholecalciferol) Tablets, Merck & Co., Inc., Labeling Revision
  • Norditropin (somatropin [rDNA origin]) Injection, Novo Nordisk Inc., Manufacturing Change or Addition
  • Tamsulosin Hydrochloride Capsules, IMPAX Laboratories, Inc., Approval
  • Temozolomide Capsules, Barr Laboratories, Inc., Approval

March 2, 2010

  • Articaine Hydrochloride and Epinephrine Injection, TechReg Services, Inc., Approval
  • Cefoxitin Injection, West-Ward Pharmaceutical Corp., Approval
  • Hydralazine Hydrochloride Tablets, Zydus Pharmaceuticals USA, Approval
  • Janumet (metformin hydrochloride and sitagliptin phosphate) Tablets, Merck, Efficacy Supplement with Clinical Data to Support
  • Januvia (sitagliptin phosphate) Tablets, Merck Co. Inc., Efficacy Supplement with Clinical Data to Support
  • Wellbutrin (bupropion hydrochloride) Tablets, GlaxoSmithKline, Labeling Revision
  • Wellbutrin (bupropion hydrochloride) Tablets, GlaxoSmithKline, Labeling Revision
  • Wellbutrin XL (bupropion hydrochloride) Extended-Release Tablets, Biovail Technologies, Ltd., Labeling Revision
  • Vpriv (velaglucerase alfa) Injection, Shire Human Genetic Therapies, Inc., Approval
  • Zyban (bupropion hydrochloride) Extended-Release Tablets, GlaxoSmithKline, Labeling Revision
  • Zyrtec Allergy (cetirizine hydrochloride) Tablets, McNeil Consumer Healthcare, Labeling Revision

March 1, 2010

CDER Meetings
CDER Links

Guidance

Approved Drugs

Approval Process

Electronic Submissions

Firm Registration Status

Good Manufacturing Practice Regulations

National Drug Code Directory

MedWatch: Adverse Event Reporting

Download Forms

Generic Drugs

Small Business

En Espaρol

CBER NEWS
CBER Meetings
CBER Links
About CBER 

CBER Vision & Mission 
Biologics Research, Regulatory Information, Safety & Availability, Guidances, Development & Approval, Enforcement & Compliance

News & Events (Biologics) 
What's New, Meetings & Workshops

CBER Reports 
CBER Annual Report, Performance, FDAMA, PDUFA, FDAAA, PREA

Biologics Regulated Products 
Allergenics, Blood & Blood Products, Cellular & Gene Therapy Products, Tissue & Tissue Products, Vaccines, Xenotransplantation

Contacts in the Center for Biologics Evaluation & Research (CBER) 
Consumer questions, manufacturer's assistance, media inquiries, technical questions, requesting speakers, establishment registration...

Jobs at the Center for Biologics Evaluation and Research (CBER) 

Frequently Asked Questions about the Center for Biologics Evaluation and Research (CBER) and the Products CBER Regulates 

Biologics Electronic Reading Room (eFOI) 
Documents frequently requested through the Freedom of Information Act.

 

CDRH NEWS

March 5, 2010

March 3, 2010

March 2, 2010

CDRH Meetings
CDRH Links
Guidance Documents (Medical Devices) 

How to Market Your Device 

Postmarket Requirements (Devices) 

Importing and Exporting Devices 

International Information (Devices) 

Device Classification 

Bioresearch Monitoring 

FDA eSubmitter 

CDRH Learn 

Weekly CFR Rule Changes - Friday - 520, 522, 524, 526
Thursday - 333
Tuesday - 522, 558

Fri, March 05, 2010
RULES - NONE
New Animal Drugs:
     Change of Sponsor
     10165–10168 [2010–4560]  
[TEXT]  [PDF]
 
NOTICES
Meetings:
     Strengthening the Center for Devices and Radiological Health's 510(k) Review Process
     10294–10295 [2010–4662]   [TEXT]  [PDF]
 
Thurs, March 04, 2010
RULES - NONE
Topical Acne Drug Products for Over-The-Counter Human Use:
     Classification of Benzoyl Peroxide as Safe and Effective and Revision of Labeling to Drug Facts Format
     9767–9777 [2010–4424]   [TEXT]  [PDF]
 
NOTICES - NONE
Denial of Hearing; Final Debarment Order:
     James A. Holland
     9904–9905 [2010–4449]   [TEXT]  [PDF]

Guidance For Industry:
     Characterization and Qualification of Cell Substrates and Other Biological Materials, etc.
     9905–9906 [2010–4553]   [TEXT]  [PDF]
 
Wed, March 03, 2010
RULES - NONE

 
NOTICES
Agency Information Collection Activities; Proposals, Submissions, and Approvals:
     Manufactured Food Regulatory Program Standards
     9605 [2010–4340]   [TEXT]  [PDF]
 
Tue, March 02, 2010
RULES - NONE
Implantation or Injectable Dosage Form New Animal Drugs:
     Tilmicosin
     9333–9334 [2010–4206]   [TEXT]  [PDF]

New Animal Drugs for Use in Animal Feeds:
     Chlortetracycline
     9334 [2010–4205]   [TEXT]  [PDF]
 
NOTICES
Advisory Committee Information Hotline
9416–9418 [2010–4258]   [TEXT]  [PDF]

Meetings:
     Oncologic Drugs Advisory Committee
     9419–9420 [2010–4261]   [TEXT]  [PDF]
     Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee
     9422–9423 [2010–4260]   [TEXT]  [PDF]
     Pulmonary-Allergy Drugs Advisory Committee
     9420 [2010–4262]   [TEXT]  [PDF]
     Tobacco Products Scientific Advisory Committee
     9422 [2010–4195]   [TEXT]  [PDF]
 
Mon, March 01, 2010
RULES

 
NOTICES
Agency Information Collection Activities; Proposals, Submissions, and Approvals:
     Human Tissue Intended for Transplantation
     9226–9227 [2010–4066]   [TEXT]  [PDF]
     Pretesting of Tobacco Communications
     9225–9226 [2010–4098]   [TEXT]  [PDF]

Determinations of Regulatory Review Periods for Purposes of Patent Extensions:
     Firmagon
     9227–9228 [2010–4159]   [TEXT]  [PDF]

Draft Guidance for Industry:
     Non-Inferiority Clinical Trials; Availability
     9228–9229 [2010–4109]   [TEXT]  [PDF]

Public Workshop:
     Measuring Progress on Food Safety: Current Status and Future Directions
     9232–9233 [2010–4110]   [TEXT]  [PDF]
 
 
 
 

GXP Academy  |  Conferences  |  Discussions  |  FDA.COM Job Board  |  On-Demand Printing - Custom CRFs

New!  -  GLP Master Handbook - 2009 Canadian GMPs - Eudralex Pharmacovigilance Volume 9a Electronic Systems Master Handbook |  Fax Form

The e-Newsletter of
What's New with CDER, CDRH & CBER
Distributed by the worlds leader in Federal Regulations,
GMP Publications, Inc.  & FDA.COM
Tel: 866-GXPNews (or 856-810-7331)  Fax: 856-810-7339
http://www.gmppublications.com / http://www.fda.com    John Cuspilich, Sr. Editor, GXPNews

If you would like to advertise in this eNewsletter, call 856-810-1825